Cancer treatment using bismuth-213 and actinium-225 in radioimmunotherapy
Radioimmunotherapy is an innovative cancer therapy in which a radioactive charge is connected to a cancer cell-specific vector in order to selectively kill the targeted tumour cells. Several alpha-emitting isotopes have been proposed for radioimmunotherapy, but all have one or more drawbacks. The most attractive alpha-emitting nuclide turned out to be Bi-213, which has only a relatively small fraction of hard gamma-emitting daughter nuclides in its decay system, and can conveniently be made available to hospitals in a radionuclide generator with its parent nuclide AC-225.
Bibliographic Reference: An article published in: Nuclear News, Volume 44, Number 13, December 2001, pp.29-33.
Record Number: 200214548 / Last updated on: 2002-04-04
Original language: en
Available languages: en